Targets › MAP2K1
26 programs from 25 companies in 241 trials: 121 Phase 2, 72 Phase 1, 25 Phase 4, 23 Phase 3; Oncology, Other, Cardiovascular; next expected readout Nov 2026.
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. (UniProt, Q02750)
Open in Phaseline: the race on MAP2K1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Trametinib Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor | MAP2K2, MAP2K1 | Phase 4 | Diffuse Astrocytoma; Melanoma; Differentiated Thyroid Cancer (DTC); EGFR-mutant Non-small Cell Lung Cancer … | Nov 2026 |
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| Pfizer | Binimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 4 | Solid Tumors; Melanoma | Jul 2029 |
| Pierre Fabre Medicament | Binimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Melanoma; Non-Small Cell Lung Cancer; Solid Tumor, Adult; Solid Tumor … | Dec 2026 |
| Verastem | avutometinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Low Grade Serous Ovarian Cancer; Low Grade Ovarian Serous Adenocarcinoma; Non Small Cell Lung Cancer; KRAS Activating Mutation … | Dec 2026 |
| Shanghai Kechow Pharma | tunlametinib MEK1/2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Colorectal Cancer Metastatic; Melanoma; Melanoma Advanced; Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation … | Dec 2026 |
| AstraZeneca | Selumetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV; Neurofibromatosis 1; Advanced Non Small Cell Lung Cancer; Tumor … | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQ-B3234 capsules Selective MEK1/2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Plexiform Neurofibroma | Dec 2027 |
| Shanghai JMT-Bio | Glumetinib MEK inhibitor | MAP2K1 | Phase 3 | Non-Small Cell Lung Cancer | Feb 2028 |
| Immuneering | Atebimetinib MEK inhibitor | MAP2K1 | Phase 3 | Pancreatic Cancer | Jun 2028 |
| Roche | Cobimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Non-small Cell Lung Cancer; Melanoma; Metastatic Distal Bile Duct Adenocarcinoma; Chronic Myelomonocytic Leukemia (CMML) … | Nov 2026 |
| CSPC ZhongQi Pharmaceutical Technology | Glumetinib MEK inhibitor | MAP2K1 | Phase 2 | Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors | Apr 2027 |
| Roche | Cobimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Non-Small Cell Lung Cancer; Ovarian Cancer | Jun 2027 |
| Peng Zhang | Fumetinib combined platinum-based double chemotherapy MEK inhibitor | MAP2K1 | Phase 2 | EGFR | Nov 2027 |
| SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Mirdametinib (PD-0325901) Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Plexiform Neurofibroma; Healthy; Slow-Flow Vascular Malformation; Advanced Unresectable Melanoma … | Dec 2028 |
| Shanghai Fosun Pharmaceutical Industrial Development | luvometinib MEK1/2 inhibitor | MAP2K1 | Phase 2 | Non-small Cell Lung Caner | Jun 2029 |
| Hanmi Pharmaceutical Company | Cobimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Advanced or Metastatic Melanoma | Sep 2029 |
| University of Alabama at Birmingham | ZEN-3694 MEK inhibitor | MAP2K1 | Phase 2 | MPNST | Nov 2031 |
| Merck KGaA | Mirdametinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 1 | Healthy | Nov 2026 |
| Recursion Pharmaceuticals | Tak-733 (REC-4881) Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 1 | Familial Adenomatous Polyposis | Jun 2027 |
| Washington University School of Medicine | Zunsemetinib MEK inhibitor | MAP2K1 | Phase 1 | Metastatic Pancreatic Ductal Adenocarcinoma; Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | Jun 2027 |
| Pasithea Therapeutics | PAS-004 MEK 1/2 inhibitor | MAP2K1, MAP2K2 | Phase 1 | RAS Mutation; NF1 Mutation | Sep 2027 |
| Genfit | GNS561 MEK inhibitor | MAP2K1 | Phase 1 | Cholangiocarcinoma | Dec 2027 |
| Nested Therapeutics | NST-628 non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway | RAF1, MAP2K1 | Phase 1 | Oncology | Nov 2028 |
| Liu Huang | Glumetinib MEK inhibitor | MAP2K1 | Phase 1 | Metastatic Colorectal Cancer | Dec 2028 |
| Haihe Biopharma | Glumetinib MEK inhibitor | MAP2K1 | Phase 1 | C-Met Exon 14 Mutation | – |
Melanoma (8) Advanced Lymphoma (6) Neurofibromatosis 1 (5) Non-Small Cell Lung Cancer (4) Neurofibromatosis Type 1 (3) Low Grade Glioma (3) Non-small Cell Lung Cancer (3) Metastatic Malignant Neoplasm in the Brain (3) Nicotine Dependence (3) MPNST (2) Metastatic Melanoma (2) Solid Tumor, Adult (2)
small molecule (18), mixed (5), antibody (1), protein or peptide (1)
Roche (2) University of Alabama at Birmingham (1) AstraZeneca (1) Pierre Fabre Medicament (1) Shanghai Kechow Pharma (1) Pasithea Therapeutics (1) Genfit (1) Novartis (1) Merck KGaA (1) SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) University of California, San Francisco (1) Nested Therapeutics (1) Verastem (1) Peng Zhang (1) Immuneering (1) Washington University School of Medicine (1) Pfizer (1) Chia Tai Tianqing Pharmaceutical Group (1) CSPC ZhongQi Pharmaceutical Technology (1) Haihe Biopharma (1)
MAP2K2 (15) ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MS4A1 (1) CHRM3 (1) CHRM2 (1) ADRB3 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.